KalVista Pharmaceuticals (KALV) Cash & Equivalents Growth (1y) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -68.22% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 988.88% |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.00% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 15.64% |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 4.77% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 17.50% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 3.35% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -4.13% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 67.78% |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 290.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 290.30% |
| Apr 30, 2025 | 314.03% |
| Oct 31, 2024 | -27.89% |
| Jul 31, 2024 | -35.54% |
| Apr 30, 2024 | -43.47% |
| Jan 31, 2024 | -72.89% |
| Oct 31, 2023 | 49.45% |
| Jul 31, 2023 | 30.49% |
| Apr 30, 2023 | 82.99% |
| Jan 31, 2023 | 86.61% |
| Oct 31, 2022 | -17.01% |
| Jul 31, 2022 | -21.68% |
| Apr 30, 2022 | -39.26% |
| Jan 31, 2022 | 157.10% |
| Oct 31, 2021 | 187.44% |
| Jul 31, 2021 | 168.36% |
| Apr 30, 2021 | 220.43% |
| Jan 31, 2021 | -4.77% |
| Oct 31, 2020 | -25.53% |
| Jul 31, 2020 | -40.17% |
| Apr 30, 2020 | -50.67% |
| Jan 31, 2020 | -66.96% |
| Oct 31, 2019 | -82.07% |
| Jul 31, 2019 | -37.37% |
| Apr 30, 2019 | -37.31% |
| Jan 31, 2019 | -3.98% |
| Oct 31, 2018 | 330.59% |
| Jul 31, 2018 | 81.70% |
| Apr 30, 2018 | 64.96% |
| Jan 31, 2018 | 75.17% |
| Oct 31, 2017 | 163.22% |
| Jul 31, 2017 | 69.30% |
| Mar 31, 2016 | 1,427.51% |
| Dec 31, 2015 | 1,278.57% |
| Sep 30, 2015 | 542.12% |
| Jun 30, 2015 | 811.11% |
| Mar 31, 2015 | -65.71% |